Eagle Rock Investment Company LLC Has $13.62 Million Position in IQVIA Holdings Inc. $IQV

Eagle Rock Investment Company LLC raised its position in IQVIA Holdings Inc. (NYSE:IQV) by 30.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 60,416 shares of the medical research company’s stock after buying an additional 14,084 shares during the quarter. IQVIA accounts for 1.9% of Eagle Rock Investment Company LLC’s holdings, making the stock its 14th biggest holding. Eagle Rock Investment Company LLC’s holdings in IQVIA were worth $13,618,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in IQV. Eubel Brady & Suttman Asset Management Inc. bought a new position in shares of IQVIA during the third quarter worth approximately $14,278,000. OPTIMAS CAPITAL Ltd bought a new stake in shares of IQVIA in the third quarter valued at approximately $4,008,000. Amundi boosted its stake in shares of IQVIA by 46.3% in the second quarter. Amundi now owns 1,279,817 shares of the medical research company’s stock valued at $210,722,000 after buying an additional 405,250 shares during the period. EDENTREE ASSET MANAGEMENT Ltd acquired a new stake in IQVIA during the third quarter worth approximately $7,368,000. Finally, Candriam S.C.A. increased its stake in IQVIA by 61.2% during the 3rd quarter. Candriam S.C.A. now owns 272,747 shares of the medical research company’s stock worth $51,806,000 after acquiring an additional 103,567 shares during the period. Institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

Shares of NYSE:IQV opened at $164.08 on Friday. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $247.04. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.75. The company has a market cap of $27.84 billion, a price-to-earnings ratio of 20.88, a PEG ratio of 1.64 and a beta of 1.39. The firm has a 50 day simple moving average of $186.70 and a 200 day simple moving average of $205.21.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. The firm had revenue of $4.36 billion for the quarter, compared to analysts’ expectations of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The company’s revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on IQV. Morgan Stanley set a $240.00 target price on IQVIA in a research report on Wednesday, February 11th. Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. TD Cowen raised shares of IQVIA from a “hold” rating to a “buy” rating and upped their price objective for the stock from $174.00 to $213.00 in a research report on Monday, March 9th. JPMorgan Chase & Co. reduced their price objective on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a research note on Friday, February 6th. Finally, Stifel Nicolaus decreased their target price on shares of IQVIA from $273.00 to $220.00 and set a “buy” rating on the stock in a report on Friday, February 6th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $229.13.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.